Erik Dubberke, MD, MSPH, Washington University School of Medicine, St. Louis, MO; Robert Orenstein, DO, Mayo Clinic Arizona, Phoenix, AZ; Paul Mariani, MD, Sanford Health, Fargo, ND; Kathleen Mullane, DO, FIDSA, University of Chicago Medicine, Chicago, IL; Mary Kay Sobcinski, RN, MHA, Rebiotix Inc, Roseville, MN
Download this poster (197 KB)
Download the abstract (31 KB)
Infectious Diseases Week 2014
October 8-12, 2014, Philadelphia, PA
The purpose of the PUNCH CD study was to assess the safety of RBX2660 (microbiota suspension) for recurrent infection (CDI). RBX2660 is a biologic drug consisting of a suspension of live human derived intestinal microbes. A secondary objective of the study was CDI resolution at 8 weeks.